Angle Files De Novo Submission For Parsortix System In Breast Cancer
Executive Summary
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
You may also be interested in...
Angle Is Ready To Capitalize On Promise Of Capture Cell Technology
Angle PLC has published half year interim results which indicate it will capitalize on a new liquid biopsy market.
Angle Will Reshape Liquid Diagnostics By Capturing Circulating Tumor Cells
Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.